Published 6 months ago on January 11, 2021 By Kyle Jaeger
The Food and Drug Administration (FDA) announced on Friday that it will be taking steps in the coming months to fill gaps in research about the safety and efficacy of CBD. Since hemp and its derivatives like cannabidiol were federally legalized under the 2018 Farm Bill, FDA has been developing regulations for products containing them. But the agency has been taking its time as it works to improve and expand data on the use and effects of CBD. In a new letter, FDA Commissioner Stephen Hahn and Principal Deputy Commissioner Amy Abernethy noted the “rapid increase in the interest and availability” of the products but pointed out that “we still have a limited understanding of the safety profile of CBD and many other cannabis-derived compounds, including potential safety risks for people and animals.”